Skip to content

Study · Systematic review · 2026

7 results

Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Kaur R, Singh A

Diabetes, obesity & metabolism23 Jun 2026Cited by 1 (Europe PMC)

PMID42337824 (opens in a new tab)PMCIDPMC13448877 (opens in a new tab)DOI10.1111/dom.71031 (opens in a new tab)PepBankPUB-42337824
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In an exploratory network meta-analysis in adults with CKD, subcutaneous semaglutide ranked highest for kidney composite outcomes (SUCRA 78.4%).

    In plain wordsIn adults with kidney disease, injected semaglutide ranked first among GLP-1 drugs for kidney outcomes in an exploratory comparison.

    Peptide
    Semaglutide
    Outcome
    Not applicableNetwork meta-analysis ranking for kidney composite outcome
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists in the network
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    SUCRA
    78.4%
    semaglutide

    Source sentences

    Summary
    Semaglutide ranked highest in the NMA (SUCRA 78.4%).
    2 context sentences
    Summary · context
    semaglutide subcutaneous achieved the highest SUCRA ranking for kidney composite outcomes
    Summary · context
    Eligible RCTs enrolled adults with CKD (eGFR 2 or UACR ≥ 30 mg/g) comparing GLP-1 RAs versus placebo for ≥ 26 weeks.

Studies that did not test the peptide alone6

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with CKD, pooled GLP-1 receptor agonists (including semaglutide) reduced 3-point MACE by 16% versus placebo.

    In plain wordsIn adults with kidney disease, GLP-1 drugs as a group lowered major heart events by 16% compared with placebo.

    Peptide
    Semaglutide
    Outcome
    Decrease3-point MACE
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    MACE reduction
    16%
    pooled GLP-1 RA
    Hazard ratio
    0.84
    MACE

    Source sentences

    Summary
    GLP-1 RAs reduced MACE by 16% (HR 0.84, 95% CI 0.79-0.89
    1 context sentence
    Summary · context
    Eligible RCTs enrolled adults with CKD (eGFR 2 or UACR ≥ 30 mg/g) comparing GLP-1 RAs versus placebo for ≥ 26 weeks.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with CKD, pooled GLP-1 receptor agonists (including semaglutide) reduced the composite kidney endpoint by 21% versus placebo.

    In plain wordsIn adults with kidney disease, GLP-1 drugs as a group lowered a combined measure of kidney problems by 21% compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseComposite kidney endpoint
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary

    Measurements

    Composite kidney endpoint reduction
    21%
    pooled GLP-1 RA
    Hazard ratio
    0.79
    kidney composite

    Source sentences

    Summary
    the composite kidney endpoint by 21% (HR 0.79, 95% CI 0.73-0.86
    1 context sentence
    Summary · context
    Eligible RCTs enrolled adults with CKD (eGFR 2 or UACR ≥ 30 mg/g) comparing GLP-1 RAs versus placebo for ≥ 26 weeks.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with CKD, pooled GLP-1 receptor agonists (including semaglutide) reduced kidney failure risk by 28% versus placebo.

    In plain wordsIn adults with kidney disease, GLP-1 drugs as a group lowered the risk of kidney failure by 28% compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseKidney failure risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary

    Measurements

    Kidney failure risk reduction
    28%
    pooled GLP-1 RA
    Hazard ratio
    0.72
    kidney failure

    Source sentences

    Summary
    Kidney failure risk was reduced by 28% (HR 0.72)
    1 context sentence
    Summary · context
    Eligible RCTs enrolled adults with CKD (eGFR 2 or UACR ≥ 30 mg/g) comparing GLP-1 RAs versus placebo for ≥ 26 weeks.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with CKD, pooled GLP-1 receptor agonists (including semaglutide) decreased UACR by 26% versus placebo.

    In plain wordsIn adults with kidney disease, GLP-1 drugs as a group lowered urine protein loss by 26% compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseUrine albumin-creatinine ratio (UACR)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary

    Measurements

    UACR decrease
    26%
    pooled GLP-1 RA

    Source sentences

    Summary
    UACR decreased by 26%.
    1 context sentence
    Summary · context
    Eligible RCTs enrolled adults with CKD (eGFR 2 or UACR ≥ 30 mg/g) comparing GLP-1 RAs versus placebo for ≥ 26 weeks.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 06HumanNot a test of Semaglutide aloneSystematic reviewOther

    In adults with CKD, the benefits of pooled GLP-1 receptor agonists (including semaglutide) were consistent irrespective of SGLT2 inhibitor background use.

    In plain wordsIn adults with kidney disease, the benefits of GLP-1 drugs as a group were similar whether or not people also took an SGLT2 inhibitor.

    Peptide
    Semaglutide
    Outcome
    No significant changeEffect modification by SGLT2 inhibitor background use
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Interaction p value
    0.41
    SGLT2 inhibitor background

    Source sentences

    Summary
    Benefits were consistent irrespective of SGLT2 inhibitor background use (interaction p = 0.41).
    1 context sentence
    Summary · context
    Eligible RCTs enrolled adults with CKD (eGFR 2 or UACR ≥ 30 mg/g) comparing GLP-1 RAs versus placebo for ≥ 26 weeks.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 07HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with CKD, pooled GLP-1 receptor agonists (including semaglutide) showed no excess acute kidney injury risk versus placebo.

    In plain wordsIn adults with kidney disease, GLP-1 drugs as a group did not raise the risk of sudden kidney injury compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeAcute kidney injury risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Kidney and urinary

    Source sentences

    Summary
    No excess acute kidney injury risk was observed.
    1 context sentence
    Summary · context
    Eligible RCTs enrolled adults with CKD (eGFR 2 or UACR ≥ 30 mg/g) comparing GLP-1 RAs versus placebo for ≥ 26 weeks.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.